Population Effect of Differences in Cholesterol Guidelines in Eastern Europe and the United States

Authors:

Abstract
Taken at face value, current US and European cholesterol guidelines seem to have substantial differences.1-3 Although guidelines in both regions recommend statin therapy for adults with atherosclerotic cardiovascular disease (CVD), type 1 or type 2 diabetes, and possible familial hyperlipidemia, the 2011 European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines for the management of dyslipidemias also recommend therapy for adults with severe hypertension and chronic kidney disease (CKD).1 In the United States, guidelines endorsed by the American College of Cardiology/American Heart Association (ACC/AHA) do not identify these groups as automatic candidates for statin therapy.2 Notably, the ACC/AHA and ESC/EAS guidelines differ in their approaches to identify high-risk adults in need of statin therapy for primary prevention, as well as those ultimately recommended statins for other reasons. The ACC/AHA guidelines use the Pooled Cohort Equations (PCE), which recommend statin therapy for adults aged 40 to 75 years with a 10-year risk of atherosclerotic CVD risk of 7.5% or more.2 The ESC/EAS guidelines use estimates developed from the Systematic Coronary Risk Evaluation (SCORE) project,4 which predicts the 10-year risk of CVD mortality for adults aged 40 to 65 years. Statins are recommended based on both low-density lipoprotein cholesterol (LDL-C) levels and a SCORE risk of 5% or more.1

This publication has 17 references indexed in Scilit: